Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates

分组1 - Agenus reported quarterly earnings of $0.56 per share, significantly beating the Zacks Consensus Estimate of a loss of $1.27 per share, and showing improvement from a loss of $2.04 per share a year ago, resulting in an earnings surprise of +144.27% [1] - The company posted revenues of $34.2 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 17.54%, and up from $26.84 million in the same quarter last year [2] - Over the last four quarters, Agenus has surpassed consensus EPS estimates two times and revenue estimates three times [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call and the sustainability of earnings expectations [3][4] - Agenus shares have declined about 1.3% since the beginning of the year, while the S&P 500 has seen a decline of 3.1% [3] - The current consensus EPS estimate for the upcoming quarter is $1.65 on revenues of $103.3 million, and for the current fiscal year, it is $0.54 on revenues of $213.95 million [7] 分组3 - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 42% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5][6]